NBNick Jean Burlet

Nick Jean Burlet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nick Jean Burlet has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanobody-based lateral flow assays for the detection of α-bungarotoxin in Bungarus snake venoms

    by Suthimon Thumtecho, Selma B. Belfakir, Tenna V. K. Christensen, Esperanza Rivera-De-Torre, Nick J. Burlet, Anne Ljungars, Georgina M. S. Ross, Andreas H. Laustsen

    Accurate snake identification is critical for effective antivenom treatment following snakebite envenoming, but remains a major diagnostic challenge. Here, we developed a prototype lateral flow immunoassay (LFIA) designed to distinguish krait ( Bungarus ) from cobra ( Naja ) envenoming in Southeast Asia. To enhance point-of-care utility, the assay employs variable domains of heavy-chain-only antibodies (V H Hs). The V H Hs target α-bungarotoxin (α-BuTx), a neurotoxin unique to Bungarus , with negative selection strategies to minimize cross-reactivity with α-cobratoxin in Naja venom. Our prototype LFIA detected α-BuTx with a visual limit of detection of 0.5–5 ng/mL in running buffer and spiked urine and serum samples. Additionally, the assay detected Bungarus whole venom at 50–500 ng/mL in running buffer. No cross-reactivity with Naja venom was observed at clinically relevant concentrations, with signals detected only at supraphysiological concentrations (≥50,000 ng/mL). These results support the feasibility of using V H H-based LFIAs for guiding timely, targeted antivenom administration in resource-limited settings.

  • Oligoclonal nanobody-based recombinant antivenom protects mice challenged with venom from cobras and king cobras from India

    by Arpan Samanta, Gotravalli V. Rudresha, Shirin Ahmadi, Suthimon Thumtecho, Lars Boyens-Thiele, Tasja Wainani Ebersole, Nick J. Burlet, Camilla Holst Dahl, Hmar Tlawmte Lalremsanga, Alexander K. Buell, et al.

    Snakebite envenoming causes more than 100,000 deaths annually, with India bearing nearly half of this burden. Current equine plasma–derived antivenoms suffer from variable efficacy, safety concerns, and limited cross-neutralization of geographically diverse venoms. Here, we report a rationally designed recombinant antivenom composed of five nanobodies (V H Hs) that target the α-neurotoxins, cytotoxins, and phospholipases A 2 prevalent in the venoms of cobra and king cobra species from India. These V H Hs were previously identified and functionally validated against homologous toxin families from African elapids. In murine preincubation and rescue models of snakebite envenoming, the cocktail prevented mortality after injection with venom from the monocled cobra ( Naja kaouthia ), both king cobra species ( Ophiophagus kaalinga and Ophiophagus hannah ) from the Western Ghats and Northeast India, and pan-Indian populations of spectacled cobra ( Naja naja ). These findings demonstrate the feasibility of developing broad-spectrum nanobody-based recombinant antivenoms with continent-wide coverage as a safe and regionally adaptable biologic for snakebite envenoming therapy.


  • Open Access

    Attenuating ETEC virulence using a heat-labile enterotoxin–blocking binding protein

    by Marcus Petersson, Jens Sivkær Pettersen, Helena Bay Henriksen, Ágnes Duzs, Monica L. Fernández-Quintero, Nick Jean Burlet, Natalia Mojica, Ute Krengel, Timothy P. Jenkins, Andrew B. Ward, et al.

    Bacterial enteric pathogens are major contributors to the global burden of diarrheal diseases and the associated consequences for human health including malnutrition, growth stunting, morbidity, and mortality. While mortality from diarrhea has decreased, incidence remains high, and better interventions for preventing disease are needed. Single-domain antibodies (i.e., VHHs), functioning as target-binding proteins in the gastrointestinal tract, have been proposed as a potential approach to mitigate bacterial pathogenesis. Here, we describe a mitigation strategy where precision binding of a bivalent VHH to the receptor-binding B-pentamer of heat-labile enterotoxin aggregates the AB5 toxin and impairs enterotoxigenic Escherichia coli colonization in a flow chamber model simulating the human intestine. The VHH construct also binds to the structurally similar cholera toxin and effectively abrogates its intestinal cell cytotoxicity in vitro. Based on these results, we believe that targeting virulence could emerge as a new strategy for the management of bacterial enteric pathogens, supporting gut health in at-risk populations alongside vaccination campaigns or in populations without access to vaccines.


  • Top Cited Papers
    Open Access

    Nanobody-based recombinant antivenom for cobra, mamba and rinkhals bites

    by Shirin Ahmadi, Nick J. Burlet, Melisa Benard-Valle, Alid Guadarrama-Martínez, Samuel Kerwin, Iara A. Cardoso, Amy E. Marriott, Rebecca J. Edge, Edouard Crittenden, Edgar Neri-Castro, et al.

    Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option 1 . Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species 2 . There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms 3 . Here we addressed this challenge by immunizing an alpaca and a llama with the venoms of 18 different snakes, including mambas, cobras and a rinkhals, constructing phage display libraries, and identifying high-affinity broadly neutralizing nanobodies. We combined eight of these nanobodies into a defined oligoclonal mixture, resulting in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin families or subfamilies. This antivenom effectively prevented venom-induced lethality in vivo across 17 African elapid snake species and markedly reduced venom-induced dermonecrosis for all tested cytotoxic venoms. The recombinant antivenom performed better than a currently used plasma-derived antivenom and therefore shows considerable promise for comprehensive, continent-wide protection against snakebites by all medically relevant African elapids.


  • Open Access

    Structural mechanisms behind the neutralisation of long-chain α-neurotoxins by broadly neutralising VHHs discovered using a consensus antigen

    by Anna Damsbo, Nick J. Burlet, Monica L. Fernández-Quintero, Melisa Benard-Valle, Max D. Overath, Alid Guadarrama-Martínez, Anneline Vlamynck, Ida Bisbo, Cesar Villalobos, Tulika Tulika, et al.

    Snakebite envenoming, a neglected tropical disease, affects millions globally, causing significant morbidity and mortality. Developing broadly neutralising monoclonal antibodies offers a promising approach to address the antigenic variation present in snake venoms. In this study, we designed a long-chain consensus α-neurotoxin, LCC, to serve as an antigen in a phage display-based antibody discovery campaign. Utilising a yeast expression system, we expressed LCC and identified 21 variable domains of heavy-chain-only antibodies (VHHs) from immune libraries. These VHHs were assessed for their binding affinity to various long-chain α-neurotoxins and their neutralising capability in vitro. The VHH with the broadest cross-reactivity and highest affinity, TPL1158_01_C09, was co-crystallised with α-cobratoxin to elucidate its binding mechanism. In vivo rodent studies demonstrated the neutralisation potential of TPL1158_01_C09. Our findings highlight that the use of a consensus toxin as an antigen coincided with the discovery of broadly neutralising VHHs against snake venom toxins.


  • Open Access

    Discovery of broadly neutralizing V H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen

    by Anna Damsbo, Melisa Benard-Valle, Tom Jansen, Nick J. Burlet, Max D. Overath, Alid Guadarrama-Martínez, Kim Boddum, Alejandro Alagon, Esperanza Rivera-De-Torre, Andreas H. Laustsen

    Snakebite envenoming is a neglected tropical disease that afflicts millions of people globally, leading to substantial morbidity and mortality. Developing novel antivenoms, particularly recombinant antivenoms based on broadly neutralizing monoclonal antibodies, offers a promising strategy to address the challenge posed by venom variability. However, the extensive diversity of snake venom toxins across species and geographical regions makes this goal inherently complex. Consequently, there is a pressing need for robust discovery methodologies capable of identifying broadly neutralizing antibodies with high affinity and functional potency against a wide range of toxin families. In this study, we engineered a short-chain consensus (SCC) α-neurotoxin to serve as an antigen for a phage display – based antibody discovery campaign. The SCC was expressed using a yeast system, enabling the identification of seven variable domains of heavy-chain-only antibodies (VHHs) from immune libraries. These VHHs exhibited nanomolar-binding affinities and low dissociation rates across a panel of short-chain α-neurotoxins, which translated into in vitro neutralization, protecting the target receptor. The best two VHHs also conferred protection against lethality in a rodent model. These results highlight the unexpected value of consensus toxins in antibody discovery and offer a viable route for developing recombinant antivenoms with broad-spectrum efficacy.


  • Top Cited Papers
    Open Access

    De novo designed proteins neutralize lethal snake venom toxins

    by Susana Vázquez Torres, Melisa Benard Valle, Stephen P. Mackessy, Stefanie K. Menzies, Nicholas R. Casewell, Shirin Ahmadi, Nick J. Burlet, Edin Muratspahić, Isaac Sappington, Max D. Overath, et al.

    Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more1,2. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage3 and inhibition of nicotinic acetylcholine receptors, resulting in life-threatening neurotoxicity4. At present, the only available treatments for snakebites consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs5,6,7. Here we used deep learning methods to de novo design proteins to bind short-chain and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtained protein designs with remarkable thermal stability, high binding affinity and near-atomic-level agreement with the computational models. The designed proteins effectively neutralized all three 3FTx subfamilies in vitro and protected mice from a lethal neurotoxin challenge. Such potent, stable and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our results highlight how computational design could help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for the development of therapies for neglected tropical diseases.


  • Open Access

    De novo designed proteins neutralize lethal snake venom toxins

    by David Baker, Susana Vazquez Torres, Melisa Benard Valle, Stephen Mackessy, Stefanie Menzies, Nicholas Casewell, Shirin Ahmadi, Nick Burlet, Edin Muratspahić, Isaac Sappington, et al.

    Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more1,2. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage3 and inhibition of nicotinic acetylcholine receptors (nAChRs) resulting in life-threatening neurotoxicity4. Currently, the only available treatments for snakebite consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs5,6,7. Here, we use deep learning methods to de novo design proteins to bind short- and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtain protein designs with remarkable thermal stability, high binding affinity, and near-atomic level agreement with the computational models. The designed proteins effectively neutralize all three 3FTx sub-families in vitro and protect mice from a lethal neurotoxin challenge. Such potent, stable, and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective, and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our computational design methodology should help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for development of therapies to neglected tropical diseases


  • Open Access

    A comparative study of the performance of E. coli and K. phaffii for expressing α-cobratoxin

    by Anna Damsbo, Charlotte Rimbault, Nick J. Burlet, Anneline Vlamynck, Ida Bisbo, Selma B. Belfakir, Andreas H. Laustsen, Esperanza Rivera-De-Torre


  • Open Access

    Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies

    by Suthimon Thumtecho, Nick J. Burlet, Anne Ljungars, Andreas H. Laustsen

    Snakebite envenoming is a significant global health challenge, and for over a century, traditional plasma-derived antivenoms from hyperimmunized animals have been the primary treatment against this infliction. However, these antivenoms have several inherent limitations, including the risk of causing adverse reactions when administered to patients, batch-to-batch variation, and high production costs. To address these issues and improve treatment outcomes, the development of new types of antivenoms is crucial. During this development, key aspects such as improved clinical efficacy, enhanced safety profiles, and greater affordability should be in focus. To achieve these goals, modern biotechnological methods can be applied to the discovery and development of therapeutic agents that can neutralize medically important toxins from multiple snake species. This review highlights some of these agents, including monoclonal antibodies, nanobodies, and selected small molecules, that can achieve broad toxin neutralization, have favorable safety profiles, and can be produced on a large scale with standardized manufacturing processes. Considering the inherent strengths and limitations related to the pharmacokinetics of these different agents, a combination of them might be beneficial in the development of new types of antivenom products with improved therapeutic properties. While the implementation of new therapies requires time, it is foreseeable that the application of biotechnological advancements represents a promising trajectory toward the development of improved therapies for snakebite envenoming. As research and development continue to advance, these new products could emerge as the mainstay treatment in the future.